Interactions between estrogen and bone morphogenetic proteins in breast cancer cells by Virtanen, Heidi-Marja
Interactions between estrogen and bone
morphogenetic proteins in breast cancer
cells
Master’s Thesis
Heidi-Marja Virtanen
BioMediTech (BMT)
University of Tampere
May 9th 2016
ii
Acknowledgements
This thesis was carried out in the Cancer Genomics research group in BioMediTech, University of
Tampere. Firstly, I want to thank the group leader Anne Kallioniemi for giving me the opportunity to
do my Master’s thesis in her group. She has been, despite her myriad of other occupations, supportive
and advisable since the beginning. I’m also grateful to Emma-Leena Alarmo, who guided me through
my laboratory studies, and helped me in many things.
I want to thank Minna Ampuja for her advice, and overall, for being such a positive influence in our
office. Thanks to Kati Rouhento for guiding me with the practical work. I also thank everyone else
in our group.
Thanks to my fellow students for your friendship and the good memories. I also want to thank my
family for all their support. You mean everything to me.
Tampere, May 2016
Heidi-Marja Virtanen
iii
PRO GRADU -TUTKIELMA
Paikka:  TAMPEREEN YLIOPISTO,
BioMediTech (BMT)
Tekijä:  VIRTANEN, HEIDI-MARJA ANNELI
Otsikko: Estrogeenin ja BMP:iden interaktiot rintasyöpäsolulinjoissa
Sivumäärä: 48 sivua
Ohjaajat: Professori Anne Kallioniemi ja FT Emma-Leena Alarmo
Tarkastajat: Apulaisprofessori Heli Skottman ja Professori Anne Kallioniemi
Päiväys: Toukokuu 2016
__________________________________________________________________
Tiivistelmä
Tutkimuksen tausta ja tavoitteet: Rintasyövän riskitekijöinä ovat usein erinäiset hormonaaliset
tekijät, ja erityisesti estrogeenilla on todettu olevan edistävä vaikutus rintasyöpäkasvaimen syntyyn
ja kasvuun. Luun morfogeneettiset proteiinit (BMP) ovat ryhmä kasvutekijöitä, jotka on liitetty
erilaisiin syöpiin, kuten rintasyöpään. BMP:illä on havaittu olevan erilaisia vaikutuksia
rintasyöpäsoluihin, vähentäen joidenkin kasvua, ja puolestaan lisäten joidenkin liikkumista ja
levittäytymistä. Estrogeeni- ja BMP-signalointireittien on todettu olevan yhteydessä toisiinsa, ja ne
voivat vaikuttaa toistensa toimintaan. Tässä tutkimuksessa tavoitteena on selvittää estrogeenin
vaikutusta BMP:iden geeniekspressioon kuudessa eri rintasyöpäsolulinjassa, sekä tutkia estrogeenin
ja BMP4:n vaikutusta solukasvuun kahdessa rintasyöpäsolulinjassa.
Tutkimusmenetelmät: Rintasyöpäsolulinjoja (estrogeenireseptoripositiiviset BT-474, MCF-7,
MDA-MB-361, T-47D ja ZR-75–30, sekä estrogeenireseptorinegatiivinen MDA-MB-231)
kasvatettiin estrogeenivapaissa olosuhteissa kolmen päivän ajan, jonka jälkeen ne käsiteltiin 17b-
estradiolilla (E2, 100 nM) tai vehikkelikontrollilla. BMP4:n ja BMP7:n, sekä positiivikontrolli-
geenien GREB1 ja TFF1 ilmenemistasot määritettiin 24h ja 48h altistuksen jälkeen qRT-PCR:lla
käyttäen SYBR Green I -väriin pohjautuvaa menetelmää. Solukasvun tutkimista varten BT-474 ja T-
47D-soluja kasvatettiin kolmen päivän ajan estrogeenivapaassa mediumissa, jonka jälkeen ne
käsiteltiin E2:lla (100 nM), ihmisen rekombinantti BMP4:llä (100 ng/ml), molemmilla näistä, tai
vehikkelikontrollilla. Kasvua seurattiin mikroskopoimalla ja kuvaamalla soluja, lisäksi solumäärä
laskettiin kuusi (T-47D) tai seitsemän (BT-474) päivää altistuksien jälkeen.
Tutkimustulokset: Positiivikontrolligeenien GREB1 ja TFF1 ekspressio lisääntyi odotetusti
suurimmassa osassa estrogeenireseptoripositiivisia solulinjoja estrogeenikäsittelyn jälkeen. E2-
käsittely vaikutti eri solulinjojen BMP4- ja BMP7-ekspressioon eri tavoin. BMP4:n ekspressio laski
merkittävästi BT-474-, MCF-7- ja MDA-MB-361-solulinjoissa, mutta muissa ei näkynyt merkittävää
muutosta E2-käsittelyn jälkeen. BMP7-ekspressio laski BT-474-, T-47D- ja ZR-75-30-solulinjoissa,
muissa ei jälleen havaittu merkittävää muutosta. Solukasvueksperimentissä estrogeeni lisäsi
odotusten mukaisesti solukasvua sekä BT-474- että T-47D-solulinjassa. E2- ja BMP4-käsiteltyjen
solujen kasvu oli huomattavasti vähäisempää kuin pelkällä estrogeenilla käsiteltyjen solujen.
Johtopäätökset: Estrogeeni vaikuttaa eri tavoin BMP4- ja BMP7-ekspressioon riippuen solulinjasta.
Osassa solulinjoja se laskee ekspressiota, ja osan ekspressioon se ei vaikuta merkittävästi. BMP4
kykeni vähentämään estrogeenin aiheuttamaa rintasyöpäsolujen kasvun kiihtymistä. Tämä löydös on
erittäin mielenkiintoinen, ja sillä saattaa olla kliinistä merkitystä rintasyöpäpotilaiden hoidossa.
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Abstract
Background and aims: Breast cancer is the second most common cancer in the world after lung
cancer, and the most common cancer among women. The risk factors for breast cancer include
different hormonal factors and consequently, estrogen has been found to promote breast cancer
pathogenesis. Bone morphogenetic proteins (BMP) are a group of growth factors that have been
connected to different cancers, including breast cancer. BMPs have been noted to have different
effects on breast cancer cells, decreasing proliferation in some, and in contrast, increasing migration
and invasion in others. The estrogen and BMP signaling pathways have been shown to have a
connection, and they can influence each other’s functions. In this study, the objectives are to examine
the effect of estrogen on BMP gene expression in six breast cancer cell lines, and to study the effects
of estrogen and BMP4 on cell proliferation in two breast cancer cell lines.
Methods: The breast cancer cell lines (estrogen receptor positive BT-474, MCF-7, MDA-MB-361,
T-47D and ZR-75-30, and the estrogen receptor negative MDA-MB-231) were cultured in estrogen
free medium for three days before treatment with 17b-estradiol (E2, 100 nM) or vehicle control for
24 and 48 hours. The gene expression of BMP4 and BMP7, and the positive control genes GREB1
and TFF1 was assessed with qRT-PCR by using a SYBR Green I dye based assay. For examining the
cell proliferation, BT-474 and T-47D cells were cultured for three days in estrogen free conditions,
and treated with E2 (100 nM), human recombinant BMP4 (100 ng/ml), both, or vehicle control. The
cell proliferation was followed by microscopy and imaging, and finally by counting the cells at six
(T-47D) and seven (BT-474) days after the treatments.
Results: The expression of positive control genes GREB1 and TFF1 increased after estrogen
treatment in most estrogen receptor positive cell lines, as expected. Treatment with E2 had a variable
effect on BMP4 and BMP7 expression depending on the cell line. BMP4 expression was notably
decreased in BT-474, MCF-7 and MDA-MB-361 cell lines, but not in others. The expression of
BMP7 was notably decreased in BT-474, T-47D and ZR-75-30, but again, there was no significant
change in the others. The cell proliferation experiment showed that as expected, E2 increased cell
growth both in BT-474 and T-47D cell line, and that BMP4 was able to inhibit the effect of E2 on
cell growth.
Conclusions: Estrogen has different effects on BMP4 and BMP7 expression depending on the cell
line. In some it decreases BMP expression, and in others it has no significant effect. BMP4 was able
to diminish the estrogen induced cell proliferation. This is an important finding that may have clinical
applicability for the treatment of breast cancer patients.
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1Abbreviations
ACVR Activin receptor
BMP Bone morphogenetic protein
BMPR Bone morphogenetic protein receptor
BRAM1 BMP receptor associated molecule 1
Co-SMAD  Common mediator SMAD
CYP450 Cytochrome P450
DCIS Ductal carcinoma in situ
E1 Estrone
E2 17β-estradiol
E3 Estriol
EMT Epithelial-mesenchymal transition
ERα/β Estrogen receptor α/β
ERE Estrogen response element
ERK Extracellular signal-related kinase
HER2 Human epidermal growth factor receptor 2
I-SMAD  Inhibitory SMAD
MAPK Mitogen-activated protein kinase
PR Progesterone receptor
R-SMAD  Regulatory SMAD
SERM Selective estrogen receptor modulator
SMAD Sma- and Mad-related protein
SMURF  SMAD ubiquitin regulatory factor
TAK1 TGF-b activated kinase 1
TGF-β Transforming growth factor beta
XIAP X-linked inhibitor of apoptosis protein
21. Introduction
Breast cancer is the second most common cancer in the world after lung cancer, and the most common
in women with 1.67 million new cases in 2012 (Ferlay et al. 2015). In Finland, breast cancer is the
most common cancer with 5000 new cases per year in 2014, around 15 % of all cancer cases (Finnish
Cancer Registry 2016). Less than 1% of breast cancers occur in men (Korde et al. 2009).  Breast
cancer is only the fifth cause of death from cancer worldwide, and more women survive breast cancer
in more developed countries, where lung cancer is now number one cause of cancer death in women
(Ferlay et al. 2015). There is large variation in breast cancer mortality: in high income countries,
breast cancer survival rates are much higher (80% 5-year-survival) than in low income countries
(below 40% 5-year-survival) (Shah et al. 2014). In Finland, due to its high prevalence, breast cancer
still remains first cause of death from cancer in women (Finnish Cancer Registry 2016).
Breast cancer risks include various hormonal factors such as early menarche, late menopause,
nulliparity or late first birth, all of which increase the lifetime exposure to estrogen (Santen et  al.
2009). The effects of estrogen are mediated through the estrogen receptors ERα and ERβ, and the ER
status of a breast cancer patient is a notable prognostic indicator (Ye et al. 2009).
BMPs are extracellular signaling molecules belonging to the TGF-β superfamily that can control e.g.
proliferation, differentiation, migration and apoptosis by regulating gene transcription (Alarmo and
Kallioniemi 2010). BMPs are known to have a role in breast cancer, functioning either as pro-
metastatic agents, promoting migration and invasion or as anti-metastatic, growth inhibiting factors
(Ehata et al. 2013).
Functional cross-talk between estrogen and BMPs has been detected in some studies. BMPs have
been reported to have inhibitory effects on breast cancer cell proliferation induced by estrogen, and
estrogen has been found to be able to alter the SMAD signaling of BMPs by downregulating BMP
receptor expression (Takahashi et al. 2008).  Estrogen and BMPs may also have an effect  on each
other’s function via interactions between their receptor and downstream signaling (Ye et al. 2009).
However, the interplay between estrogen and BMPs has been studied in very few cell lines, and
information on the subject is still scarce. In this study, the effect of estrogen on BMP4 and BMP7
gene expression, and the effect of estrogen and BMP4 treatment on cell proliferation were assessed.
The gene expression studies were conducted with five estrogen receptor positive breast cancer cell
lines, and an estrogen receptor negative control breast cancer cell line. Two cell lines were treated
3with estrogen and BMP4 in order to analyze their effects on cell proliferation with both cell counting
and microscopy.
42. Literature Review
2.1. Breast cancer
Cancer is the result of a combination of many factors, such as inherited mutations or polymorphism
of cancer susceptibility genes, environmental agents influencing somatic genetic changes and several
other systemic and local factors (Polyak 2001). About 5-10% of breast cancers are hereditary, thus
the affected person has inherited a gene mutation exposing them to breast cancer
(http://www.cancer.gov/types/breast/patient/breast-treatment-pdq, accessed 9.3.2016). BRCA1 and
BRCA2 are well-known genes with mutations that increase breast and ovarian cancer risk, and
possibly the risk of other cancers, too (http://www.cancer.gov/types/breast/patient/breast-treatment-
pdq, accessed 9.3.2016). In addition to mutations in high-penetrance cancer susceptibility genes
BRCA1, BRCA2, and TP53, several moderate- and low-penetrance allele variants and SNPs in
FGFR2 (fibroblast growth factor receptor 2), TNRC9 (thymocyte selection-associated high mobility
group box 9), MAP3K1 (mitogen-activated kinase kinase kinase 1), LSP1 (lymphocyte specific
protein), CASP8 (caspase 8), and TGF-β1 have been noted to be associated with breast cancer risk
(Polyak 2007).
Inherited gene mutations are risk factors only in a small portion of breast cancers. Most cases are
sporadic, occurring due to exposure to risk factors. Breast cancer risk is greater when breast tissue is
prolongedly exposed to estrogen because of early menarche, nulliparity or older age at first birth, late
menopause, or hormone replacement therapy for symptoms of menopause (Shah et al. 2014). Other
risk factors include older age, family history of breast cancer, radiation therapy to chest or breast area,
alcohol consumption, and obesity (http://www.cancer.gov/types/breast/patient/breast-treatment-pdq,
accessed 9.3.2016, (Shah et al. 2014).  The molecular basis of breast cancers not caused by inherited
genetic changes is still quite poorly characterized (Polyak 2001).
Breasts consist of glandular, fibrous, and adipose tissue, and the glandular tissue contains 15 to 20
lobes (Figure 1) (Springhouse 2002). Within the lobes there are clustered acini: small, saclike duct
terminals that secrete milk when lactating (Springhouse 2002). Lactiferous ducts and sinuses drain
the lobules, and store the milk during lactation (Springhouse 2002). Ductal carcinoma, which
originates in the ductal cells, is the most common breast cancer type
(http://www.cancer.gov/types/breast/patient/breast-treatment-pdq, accessed 9.3.2016). Other breast
5cancer types include lobular carcinoma, and the uncommon inflammatory breast cancer
(http://www.cancer.gov/types/breast/patient/breast-treatment-pdq, accessed 9.3.2016).
In addition to histology, other factors are also assessed in diagnostics to help determine the prognosis
and treatment options of a patient. The estrogen receptor (ER) and progesterone receptor (PR) status
of a breast cancer patient is determined to predict response to endocrine therapy (Shah et al. 2014).
HER2 (human epidermal growth factor receptor 2) status is a prognostic factor, and it can be used to
predict response to therapies targeting the HER-2/neu receptor, such as trastuzumab (Shah et al.
2014). Gene expression profiles are used nowadays to classify breast cancers to luminal A (ERα+,
PR+,  low proliferation rate),  luminal B (ERα-, PR+, high proliferation rate), HER2-overexpressing,
and triple-negative carcinoma (shortened as TNC; ERα-, PR-, HER2-) (Huang et al. 2015). Polyak
(2007) divides the molecular subtypes in five different groups: basal-like, luminal A, luminal B,
HER2+/ER-, and normal-breast-like. The different subtypes have different clinical outcomes and
treatment responses as a result of the molecular differences (Polyak 2007).
The different subtypes are seen already in premalignant DCIS (ductal carcinoma in situ) stage, and
they are conserved in different ethnic groups, which indicates that each tumor type has a specific
tumor progression pathway (Polyak 2007). This leads to the possible explanation that a distinct cell
Figure 1:  Anatomy of the female breast. Image acquired from Springhouse (2002)
6of origin (for example cancer stem cells) and tumor subtype-specific genetic and epigenetic changes
are either both or the other responsible for the tumor heterogeneity (Polyak 2007).
2.2. Estrogen and breast cancer
Since the notion that bilateral oophorectomy resulted in breast cancer remission in premenopausal
women over a 100 years ago, the connection between breast cancer and estrogen has been recognized
(Clemons and Goss 2001). Both endogenous and exogenous estrogens have been associated with
breast cancer pathogenesis (Clemons and Goss 2001). Early menarche is a risk for both pre- and
postmenopausal women, and it has been shown that women who had early menarche (≤ 13 years),
had an almost twofold increase in risk of developing hormone receptor positive tumors (Shah et al.
2014). Overall, high endogenous sex hormone levels increase breast cancer risk (Shah et al. 2014).
Postmenopausal women with breast cancer have been shown to be exposed to more endogenous
estrogen than women without breast cancer (Feigelson and Henderson 1996). Combined estrogen and
progesterone hormone replacement therapy (HRT) for menopause symptoms is a greater risk than
oral contraceptives, since HRT is used at an older age when breast cancer risk is higher (Clemons and
Goss 2001; ESHRE Capri Workshop Group 2004). Breastfeeding has been noted to have a protective
effect (ESHRE Capri Workshop Group 2004; Feigelson and Henderson 1996; Shah et al. 2014). In
postmenopausal women, obesity increases breast cancer risk while obese premenopausal women are
surprisingly at a smaller risk of breast cancer (Clemons and Goss 2001). This is due to the effects of
excessive adipose tissue in premenopausal women: obese women often have longer menstrual cycles
and more anovulatory cycles, and are thus exposed to less estrogen in total (Clemons and Goss 2001).
In contrast, more estrogen is produced by aromatase activity in the excessive adipose tissue in
postmenopausal women, and there is a lower serum concentration of the sex-hormone binding
globulin, which is why they have higher bioavailable serum estrogen levels (Clemons and Goss
2001).
2.2.1. Normal functions of estrogen in the body
Estrogen is the primary hormone associated with the female sex: it determines the development and
regulation of female reproductive system and secondary sex characteristics. Ovaries, controlled by
the cyclically produced gonadotropins, produce most of the serum estrogen in premenopausal women
as seen in Figure 2 (Clemons and Goss 2001). In postmenopausal women, however, aromatization of
adrenal and ovarian androgens produces small amounts of estrogen in other tissues than the gonads,
e.g. liver, muscle, and fat tissue (Figure 2) (Clemons and Goss 2001). Estrogens are synthesized from
7androgens by the catalyzing action of the cytochrome P450 (CYP450) aromatase enzyme, also called
CYP19, and it has been speculated that its genetic variations may be associated with increased breast
cancer risk (Clemons and Goss 2001; Tsuchiya et al. 2005). The 17b-hydroxysteroid dehydrogenase
(17b-HSD) converts estrone (E1) to potent estradiol (E2) (Tsuchiya et al. 2005).
Estrogens play a role in several different tissue types and affect both female and male physiology
(Diel 2002). Generally, tissues with reproductive functions, such as mammary glands, ovaries, vagina
and uterus, where estrogen stimulates cell proliferation and the biosynthesis of progesterone receptors
(PR), have the highest numbers of estrogen receptors (ER) (Diel 2002). However, estrogen also acts
in non-classical target tissues i.e. brain, bones, cardiovascular system, kidneys, immune system and
liver (Diel 2002). Development of secondary sexual characteristics, regulation of gonadotropin
secretion for ovulation, maintenance of bone mass, regulation of lipoprotein synthesis and insulin
responsiveness, and maintenance of cognitive function are examples of estrogen’s functions in the
female  body  (Nelson  and  Bulun  2001).  The  development  of  mammary  glands  starts  during
embryogenesis, but only after the onset of puberty does the initiation of the ovarian steroid hormone
production induce the outgrowth of the ducts (Hynes and Watson 2010). The repeated estrous cycles
cause the ductal network to grow increasingly complex (Hynes and Watson 2010). Functionally,
Figure 2: Effects of whole-body and locally synthesized estrogen on multiple organs.
Arrows indicate sites where androgen is converted to estrogen. Figure acquired from
Clemons and Goss (2001).
8breasts mature during pregnancy, when the milk-producing structures are formed (Hynes and Watson
2010).
Estradiol (E2) is a steroid hormone, and the primary of the three major naturally occurring estrogens,
estrone  (E1)  and  estriol  (E3)  being  the  other  two.  E2  applies  its  effect  after  binding  to  estrogen
receptors α (ERα) and ERβ, after which the ER dimerizes and binds to nuclear estrogen response
elements (EREs), initiating transcription, or tethering to other transcription factors, such as AP1
(activation protein 1) and SP1 (specificity protein 1) (Figure 3) (Band and Laiho 2011; Simpson and
Santen 2015). ERα regulates gene transcription via formation of a multiprotein complex, which
contains general transcription factors, co-activator, co-repressors, co-integrators, histone
acetyltransferases (HAT) and histone deacetylases (HDAC), providing tissue- and context-specific
activation of ERα signaling (Band and Laiho 2011). Their activity not only limited to the nucleus,
ERs in the plasma membrane and mitochondria also have a role in cell signaling (Simpson and Santen
2015). Contrary to the classic model of estrogen response, non-genomic estrogen activation pathways
with rapid E2 effects have been described (Figure 3) (Hewitt et al. 2016; Simpson and Santen 2015).
The membrane-associated mediators of these events are not yet fully known, but GPER (G protein
coupled ER) is suspected to be a potential mediator of the rapid membrane localized hormone
Figure 3: Classical and non-classical mechanisms of estrogen action. In the classical pathway,
estrogen regulates gene transcription via the nuclear ERs by tethering to EREs, initiating
transcription. The non-classical routes induce rapid changes in cells, exerted by estrogen. Image
acquired and edited from Boulware and Mermelstein (2005)
9response (Hewitt et al. 2016). However, the rapid estrogen response signaling pathways are complex,
and differ between cell types (Simpson and Santen 2015).
The localization and distribution of ERa and ERb varies in pre- and postmenopausal women: ERa
is found mostly in the inner layer of epithelial cells that line the acini and intralobular ducts, and in
the myoepithelial cells of the external layer of interlobular ducts, while ERb is localized more widely
in epithelial and stromal cells in premenopausal women (Huang et al. 2015). Less than 10% of normal
mammary epithelial cells express ERa, and more than 50% express ERb in postmenopausal women
(Huang et al. 2015). Corresponding to premenopausal women, ERb is expressed in stromal cells in
postmenopausal women, but not ERa (Huang et al. 2015).
2.2.2. Effects of estrogen on breast cancer development and growth
Estrogen and ER signaling is important both in normal mammary gland development and breast
carcinogenesis. Experimental data strongly indicates that estrogens have a role in the development
and growth of breast cancer (Clemons and Goss 2001). ERα is responsible for the proliferative effect
of estrogen, and recent studies have shown that as normal breast tissue transitions to DCIS, the
number of ERα-positive cells increases, whereas ERβ-positive cell number decreases (Huang et al.
2015). The correlation between ERα and ERβ status and breast cancer survival outcome has been
demonstrated in several studies (Huang et al. 2015). ERα is generally regarded as a good indicator
for endocrine therapy and breast cancer survival, and its loss indicates invasiveness and poor
prognosis (Huang et al. 2015).
High levels of estrogen-receptors have been directly correlated with elevated risk of breast cancer
(Clemons and Goss 2001). Estrogen-receptor levels are generally low in normal mammary tissue, but
they vary between women, usually increasing with age, especially in white women compared to
Japanese or black women (Clemons and Goss 2001). The increase of estrogen receptors may be a
consequence of down-regulation failure, caused possibly by the loss of a tumor-suppressor gene
function (Clemons and Goss 2001).
Santen et al. (2009) suggest a combination of two theories of the involvement of estrogen in breast
cancer carcinogenesis: (i) estrogens cause proliferation, and the increase in cell divisions exposes the
mammary cells to more mutations, which, if unrepaired, enable the cells to become cancerous and
(ii) estrogens may be metabolized into genotoxic metabolites, or create reactive oxygen species by
redox cycling, which can damage DNA, causing mutations. They also concluded that apparently some
of estrogen’s effects on breast tumorigenesis occur independently of ER’s, which implies that
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blocking estradiol metabolite formation without lowering the actual estradiol levels might reduce
breast cancer risk (Santen et al. 2009). High levels of estrogen metabolite 4-hydroxyestradiol, which
generates DNA damaging free radicals from reductive oxidative-cycling, have been detected in
benign and malignant mammary tumors (Tsuchiya et al. 2005). CYP1B1, catalyzing 4-hydroxylation
of estrogens, is mainly expressed in estrogen target tissues, and its expression levels have been noted
to be elevated in tumor tissues (Tsuchiya et al. 2005). Thus, local formation of 4-hydroxyestradiol by
CYP1B1 is implied to play a role in breast carcinogenesis, with CYP1B1 as a notable influence
(Tsuchiya et al. 2005).
As mentioned, higher serum estrogen levels have been associated with a higher breast cancer risk in
postmenopausal  women  (Clemons  and  Goss  2001).  Breast  density,  along  with  bone  density  are
indicators of high serum estrogen levels (Clemons and Goss 2001). Women with denser breast tissue
on mammography had higher serum estrogen concentration compared to women with less dense
breasts, while hormone replacement therapy was noted to increase breast density in postmenopausal
women (Clemons and Goss 2001).
2.2.3. Endocrine therapies for breast cancer
Before the discovery of antiestrogens, e.g. the selective estrogen receptor modulator (SERM)
tamoxifen, radical operations, such as oophorectomy for premenopausal women, adrenalectomy for
postmenopausal, and hypophysectomy for both, were used to treat estrogen-responsive breast cancer
(Simpson and Santen 2015). About 70% of breast cancers are ER positive and considered hormone
sensitive, and thus are responsive to SERM treatment (Shah et al. 2014). SERMs, such as tamoxifen
and raloxifene, bind to the ER, and act either as agonists or antagonists in estrogen target tissues
(ESHRE Capri Workshop Group 2004). Differences in ER expression, receptor conformation on
ligand binding, and the expression of co-regulating proteins are factors that influence the SERM’s
agonist or antagonist activity in a given target tissue or circumstance (ESHRE Capri Workshop Group
2004).
Tamoxifen is the most used SERM in breast cancer treatment, and tamoxifen and raloxifene are both
used in breast cancer prevention (ESHRE Capri Workshop Group 2004).  Both drugs interfere with
ER binding to DNA structures by recruiting co-repressors interacting with the ERs at  the EREs in
target genes, and thus exert anti-estrogenic activity (ESHRE Capri Workshop Group 2004).
Tamoxifen and raloxifene use as preventative measure reduces breast cancer incidence by
significantly reducing ER-positive breast cancers (Chlebowski 2014). Tamoxifen better reduces
invasive breast cancers than raloxifene, and only tamoxifen reduces DCIS (Chlebowski 2014).
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Aromatase inhibitors, such as anastrozole, have been shown to be potent blockers of estradiol
production, and can be used in postmenopausal women, whose estrogen is produced solely by
aromatase (Simpson and Santen 2015). In breast cancer prevention perspective, SERMs and
aromatase inhibitors have not been directly compared, but it appears, when compared with placebo,
that aromatase inhibitors better reduce breast cancer incidence compared to tamoxifen and raloxifene
(Chlebowski 2014).
2.3. Bone morphogenetic proteins
Bone morphogenetic proteins (BMPs) are a group of extracellular signaling molecules that belong to
the TGF-b superfamily (Alarmo and Kallioniemi 2010; Carreira et al. 2014). BMPs have mitogenic,
differentiating, chemotactic, and osteolytic activities, and they mediate cell proliferation and
mesenchymal stem cell (MSC) differentiation (Carreira et al. 2014). Although originally identified
by their bone forming abilities at ectopic sites, BMPs are now known to play a critical part in different
developmental phases (Alarmo and Kallioniemi 2010; Wang et al. 2014). In many cancer types,
different BMP ligands appear to be aberrantly expressed (Ehata et al. 2013). BMPs influence different
types of cancer cells, regulating their proliferation and invasiveness, and also affect tumor
microenvironments and regulate tumor angiogenesis (Ehata et al. 2013).
BMPs constitute the largest group in the TGF-b superfamily, and around 20 BMP family members
have been characterized and divided into subgroups depending on their known functions and
similarity in sequences (Bragdon et al. 2011; Carreira et al. 2014). Not all BMPs are truly osteogenic,
for example BMP1 is in reality metalloprotease, and thus does not belong to the TGF-b superfamily
(Carreira et al. 2014). Some BMPs are also called growth and differentiation factors (GDF) (Alarmo
and Kallioniemi 2010). The known members of the BMP family include BMP2-7, BMP8A/B,
BMP10, BMP15, GDF1-3, GDF5-7, myostatin, GDF9-11 and GDF15 (Alarmo and Kallioniemi
2010). BMPs are dimeric molecules composed of two disulfide bond -linked identical monomers that
include seven conserved cysteine residues, six of which are highly conserved, forming a “cysteine
knot” motif linked by three intramolecular disulfide bonds (Alarmo and Kallioniemi 2010; Carreira
et al. 2014).
BMPs are synthesized as large, inactive precursors, containing a signal peptide guiding the protein to
the secretory pathway, a pro-domain mediating proper folding, and a C-terminal mature peptide
(Alarmo and Kallioniemi 2010; Bragdon et al. 2011; Carreira et al. 2014). The pro-domain is
proteolytically cleaved at the consensus site Arg-X-X-Arg to generate the mature and active
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homodimers or heterodimers of BMPs (Bragdon et al. 2011; Carreira et al. 2014). The pro-domain is
also thought to regulate BMP activity and availability, because it may remain non-covalently bonded
to the mature dimeric BMP secreted out of the cell (Alarmo and Kallioniemi 2010; Bragdon et al.
2011). BMPs are active both as homodimers and heterodimers, but BMP heterodimer’s, such as
BMP4/7, BMP2/6 and BMP2/7, increased potency compared to heterodimers has been shown is some
studies (Bragdon et al. 2011; Carreira et al. 2014)
BMPs have a unique ability to initiate bone formation (Alarmo and Kallioniemi 2010).
Osteoprogenitor cells, osteoblasts, chondrocytes, platelets and endothelial cells produce BMPs in
bones (Carreira et al. 2014).  BMPs  stimulate  the  differentiation  of  mesenchymal  cells  to
chondroblasts and osteoblasts, and the subsequent new bone construction during embryogenesis and
also during bone repair processes in adult tissues (Alarmo and Kallioniemi 2010; Carreira et al. 2014).
Possibly the most important BMP function is their role in in different developmental phases, from
regulation of the primal stages of embryogenesis, mesoderm formation, cardiac development,
formation of the left-right asymmetry, neural and skeletal patterning and limb formation to
organogenesis (Alarmo and Kallioniemi 2010; Wang et al. 2014). BMPs act in connection with other
growth factors, in a complex cell signaling system (Carreira et al. 2014)
2.3.1. BMP signaling
BMPs and other members of the TGF-b family share a common signaling pathway, in addition to
their common structure (Alarmo and Kallioniemi 2010; Brazil et al. 2015). BMPs activate SMAD-
dependent and various SMAD-independent signaling pathways, directly affecting gene transcription
(Bragdon et al. 2011).
The BMP receptor complex includes the BMPRI and BMPRII serine-threonine kinase receptors,
containing an N-terminal extracellular ligand binding domain, a transmembrane domain, and an
intracellular region (Carreira et al. 2014). BMP ligands bind to BMP type I receptors (BMPRI) or to
activin-like kinase (ALK) 2, 3, or 6 (Figure 4) (Brazil et al. 2015). The complex then binds to the
BMP type II receptor (BMPRII), phosphorylating the type I receptor, which in turn activates, and
phosphorylates a set of SMADs, called the receptor SMADs (R-SMAD1/5/8), which bind to SMAD4,
the  nuclear  common  SMAD  (co-SMAD)  shared  by  the  TGF-b/activin/nodal and BMP signaling
pathways (Brazil et al. 2015; Katsuno et al. 2008). R-SMADs form complexes with the co-SMAD,
and these active SMAD complexes regulate transcription of target genes in the nucleus (Alarmo and
Kallioniemi 2010). SMAD-response elements are present in BMP target genes like inhibitor or
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differentiation (Id1-3) genes, SnoN, and inhibitory SMAD6, which convey many of the downstream
effects of BMP signaling (Brazil et al. 2015).
In addition to the SMAD pathway, other, non-SMAD, intracellular pathways are activated in response
to BMP ligands (Figure 4) (Alarmo and Kallioniemi 2010). These include the MAP kinases (MAPK)
ERK, JNK and p38, phosphatidyl inositol-3 kinase (PI3K/AKT) and small GTPase pathways, which
cooperate with SMAD signaling pathways and regulate various cellular responses in target cells
(Ehata et al. 2013). It has been suggested that the pathway activation is accomplished via the protein-
protein interactions of BRAM1 (bone morphogenetic protein receptor associated molecule 1) or
XIAP (X-linked inhibitor of apoptosis protein), and downstream signaling molecules TAK1 (TGF-
b-activated kinase 1) and TAB1 (TAK1 binding protein) with BMPR-IA (Bragdon et al. 2011).
BMP signaling is widely regulated on multiple levels in cells, including intracellularly by inhibitory
SMADs 6 and 7 (I-SMAD), SMURF ubiquitin ligases, miRNAs, methylation, and also extracellularly
by pseudoreceptors such as BMP and BAMBI (activin membrane bound inhibitor) and BMP
Figure 4:  BMP signaling via the canonical, SMAD-dependent pathway or non-canonical pathways.
In the canonical pathway, as BMP ligand binds the BMPRI, they bind to BMPRII, phosphorylating
BMPRI, recruiting R-SMADs, and thus activating the SMAD pathway and regulating gene
transcription. The non-canonical pathways include for example the MAPK pathway. Image acquired
from Wang et al. (2014)
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antagonists, including Grem1 (Alarmo and Kallioniemi 2010; Brazil et al. 2015).  Extracellular  or
intracellular regulators, acting as antagonists of the BMP signaling pathway, may bind to the receptors
or sequester BMP ligands, blocking signal transduction (Carreira et al. 2014). There are also some
membrane-bound peptides that are able to enhance BMP signaling, including membrane-anchored
proteins RGMa (repulsive guidance molecule) and DRAGON (RGMb) (Alarmo and Kallioniemi
2010).
2.3.2. BMPs in cancer
BMPs are members of the TGF-b superfamily, and currently, TGF-b is widely known to exhibit bi-
directional functions in cancer progression (Band and Laiho 2011; Ehata et al. 2013). It has tumor
suppressor properties, such as inhibiting the growth of various epithelial cells, endothelial cells,
hematopoietic cells and immune cells, and inducing apoptosis of different epithelial cells (Ehata et
al. 2013). Disturbance in TGF-b signaling leads to the development of certain types of cancer, e.g.
colorectal and pancreatic cancer (Ehata et al. 2013).  On  the  other  hand,  at  later  stages  of
carcinogenesis when cancer cells have developed the ability to bypass the tumor suppressive
functions of TGF-b, they may use it for tumor progression (Band and Laiho 2011; Massagué and
Gomis 2006). Breast cancer and glioblastoma cells often lose TGFb cytostatic responses, but the
TGF-b receptors remain functional and SMADs active, leading to the utilization of the TGF-b system
to induce gene responses promoting tumor growth, invasion, evasion of immune surveillance and
metastasis (Massagué and Gomis 2006). TGF-b is also a potent inducer of epithelial-mesenchymal
transition (EMT), contributing to tumor invasion (Band and Laiho 2011; Massagué 2008).
BMPs have been reported to regulate the progression of several different types of cancer, but unlike
TGF-b, which is known to have bi-directional functions in cancer progression, the roles of BMPs in
cancer are not yet fully acknowledged (Ehata et al. 2013). The effects of BMPs in cancer cells and
tumor microenvironments are divergent: on the other hand, BMPs inhibit the proliferation of cancer
cells, with some exceptions, and induce the differentiation of certain cancer stem cells, attenuating
their aggressiveness, but they also play a critical role in tumor angiogenesis regulation and cancer
cell metastasis (Ehata et al. 2013). In vitro studies that implicate BMPs as promoting tumorigenesis
or metastasis have been reported in non-small cell lung cancer (NSCLC), renal cell carcinoma,
medulloblastoma, osteosarcoma, ovarian cancer, and an extensive variety of breast and prostate
cancer cell lines (Thawani et al. 2010). Other studies with different cell lines, however, show BMP
induced inhibition of cell proliferation (Thawani et al. 2010).
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2.3.3. BMPs in breast cancer
Not much is known of the role of BMPs in breast development, but since BMP-specific receptors are
expressed in the developing mammary gland, active BMP signaling is probable (Alarmo and
Kallioniemi 2010). Different BMP ligands have been observed to be aberrantly expressed in breast
cancer (Alarmo and Kallioniemi 2010). Breast cancer commonly metastasizes to bones, and because
of the role of BMPs in bone formation and repair, the significance of BMPs in bone metastasis has
been studied considerably (Ye et al. 2009). The SMAD-dependent BMP signaling pathway has been
shown to induce breast cancer cell invasion and bone metastasis (Katsuno et al. 2008).
BMP2, BMP6, and BMP7 are currently best known in breast cancer, and the importance of BMP4
has also been contemplated (Alarmo and Kallioniemi 2010; Kallioniemi 2012). Davies et al. (2008)
demonstrated that BMP2 and BMP7 were expressed at significantly lower levels in patients with
more aggressive breast tumors. BMP2 expression has been indicated in breast cancer cell lines,
mainly at low levels (Alarmo and Kallioniemi 2010). BMP2 has been shown to inhibit E2-induced
proliferation via the p21 up-regulation, which inhibits the E2-induced cyclin D1 –associated kinase
activity (Ye et al. 2009). However, BMP2 also has beneficial effects for the cancer cells: increased
resistance to hypoxia-induced apoptosis and promotion of motility and invasiveness of breast cancer
cells (Ye et al. 2009). The expression pattern of BMP6 in breast cancer does not differ much from
normal cells, but inactivation of BMP6 by hypermethylation has been implicated in ER-negative
breast cancer patients (Alarmo and Kallioniemi 2010; Zhang et al. 2007). Downregulation of BMP6
has been shown to enhance cell proliferation and chemoresistance, implicating that BMP6 inhibits
growth and migration (Lian et al. 2013).
BMP4 expression is increased in a subgroup of breast cancer cell lines and primary tumors
(Kallioniemi 2012). The expression of BMP4 has been shown to be elevated in 25% of breast cancer
patients, and strong expression was related to low proliferation index and increased tumor recurrence
frequency (Alarmo et al. 2013). BMP4, like BMP2, shows reduced cancer cell growth after treatment
or overexpression (Ampuja et al. 2013; Ketolainen et  al. 2010). The effect of BMP4 on migration
and invasion is somewhat controversial, with one study showing reduced (Shon et al. 2009), and
some others increased migration and invasion after BMP4 treatment (Guo et al. 2012; Ketolainen et
al. 2010). Guo et  al. (2012) demonstrated that overexpression of BMP4 promoted migration and
invasion, and on the other hand, BMP4-expression knockdown resulted in inhibited migration and
invasion activity.
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BMP7 is widely expressed in breast cancer (Alarmo et al. 2007; Alarmo et al. 2006). Decreased
BMP7 expression has been suggested to confer a specific bone metastatic potential to human breast
cancer cells (Buijs et al. 2007). The BMP7 protein expression in primary tumors is associated with
accelerated bone metastasis formation, and BMP7 expression is also a prognostic factor for early
bone metastasis (Alarmo et al. 2008). BMP7 function has been studied in breast cancer cell lines, and
in one study, the cell proliferation was stimulated by BMP7 in some cell lines, and inhibited in others
(Alarmo et al. 2009). Furthermore, exogenous BMP7 increased migration and proliferation in MDA-
MB-231 cells (Alarmo et al. 2009). Ying et al. (2015) demonstrated that BMP7 significantly inhibits
the activation of EMT-related genes induced by TGF-b1, which resulted in a significant reduction in
TGF-b1 triggered cell growth and metastasis.
2.4. Estrogen and BMP interactions
TGF-b and estrogen have extensive interactions with each other (Band and Laiho 2011), and since
BMPs  and  TGF-b share common signaling pathways, the involvement of estrogen with BMPs is
apparent. The co-SMAD of both BMP and TGF-β signaling pathways, SMAD4, was found to be a
co-repressor of transcription of ERα (Wu et al. 2003).
2.4.1. Cross-talk between TGF-β and estrogen
TGF-b and estrogen have been indicated to be co-regulated in mammary glands in a study which
found that phosphorylated SMADs and nuclear ERα were co-localized (Ewan et al. 2005). This
suggested that ERα-mediated proliferation could be restricted by TGF-b (Ewan et al. 2005). ER
activation has been reported to inhibit transcriptional activity of TGF-b reporter assays and TGF-b
induced cell migration (Band and Laiho 2011). In a microarray of TGF-b treated MCF-7 breast cancer
cells, TGF-b increased the expression of 956 genes more than twofold, and of these genes, estrogen
treatment decreased the expression of 683 genes, which suggests ERα is a major modifier of TGF-b
signaling cascade (Band and Laiho 2011). Ito et al. (2010) showed that ERα enhances the degradation
of SMAD proteins and thus inhibits TGF-b induced transcription using an ubiquitin-proteasome
pathway. The antiestrogen (tamoxifen and ICI 182.780) induced inhibition of breast cancer cell
growth has been reported to be mediated by TGF-b (Band and Laiho 2011).
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2.4.2. Cross-talk between BMPs and estrogen
Estrogen is known to modulate both BMP ligands and BMP induced responses, and evidence for a
possible relationship between ER and BMP or BMPR signaling has been shown in recent studies
(Alarmo and Kallioniemi 2010; Ye et  al. 2009). Estrogen is apparently able to regulate BMP and
BMPR expression, and it can repress the expression of some BMP receptors, e.g. BMPRIA,
BMPRIB, ACVR2A, and ACVR2B, but has no effect on ACVR1 and BMPRII (Ye et al. 2009). The
interaction  between  BMPs  and  estrogen  also  seems  to  work  the  other  way  round  with  BMPs
repressing ER action.
Cross-talk between estrogen and BMPs has been studied in several different tissues and
environments. Antiestrogens have been found to specifically upregulate BMP4 promoter activity in
human osteoblastic cells, and the effect seemed to be bone cell specific and dependent on ERα
presence (van den Wijngaard et al. 2000). The apoptotic effects of BMP7 on tissue remodeling have
been found to be opposed by estrogen in an animal study (Monroe et al. 2000). The estrogen
metabolite 16a-hydroxyestrone (16αOHE) has been implied to regulate BMPRII protein levels and
inducing angiogenesis or vascular injury–related pathways in pulmonary arterial hypertension (Fessel
et al. 2013). A BMP4-SMAD-ER molecular regulatory mechanism has been identified to regulate
the prolactin promoter’s transcriptional activity, inducing prolactin secretion in the pituitary gland
(Giacomini et al. 2009).  The  interaction  of  ER  and  BMP4  may  play  a  role  in  the  prolactinoma
formation in the pituitary gland (Giacomini et al. 2009).
A study by Helms et al. (2005) supported the view that the BMP/SMAD pathway may have a crucial
role in ER-positive breast cancer advancement, and that BMP signaling is directly linked to ER
expression, or might even be controlled by intact ER signaling. BMP2 has been shown to inhibit E2-
induced proliferation of MCF-7 breast cancer cells by inducing the expression of cyclin kinase
inhibitor p21 (Ghosh-Choudhury et al. 2000). The effect seems to be conveyed by positive cell cycle
regulatory protein inhibition (Ghosh-Choudhury et al. 2000). A study by Yamamoto et al. (2002) was
the first to connect the interactions between BMP-regulated SMADs to estrogen, by examining the
connection between ERα, SMADs and BMP2. The expression of a novel ERα-36 type ER, a splice
variant of the ERα,  has been reported to be induced by BMP2, but not the expression of the more
common ERα-66 (Wang et al. 2012).
BMP6 promoter was found to be activated by ERα in different cell types, but it had tissue-specific
actions via antiestrogen stimulation of BMP6 activity in the osteoblast-like cells, and E2 stimulation
in breast cancer and hepatoma cells (Ong et al. 2004). A study by Zhang et al. (2005) supported this
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view, and further investigated the molecular mechanisms behind the activation of BMP6
transcription, noting that E2 induction of BMP6 expression happens by ERα binding to an ERE in
the BMP6 promoter.
BMPs, by inhibiting MAPK pathways and estrogenic enzyme expression, have been reported to have
inhibitory effects on the estrogen-induced mitosis of MCF-7 breast cancer cells (Takahashi et al.
2008).  BMP2, BMP4, BMP6 and BMP7 were used alone or in combination with E2, and the cell
proliferation –inducing effect of E2 was attenuated by all of them, BMP6 and BMP7 more effectively
than BMP2 and BMP4 (Takahashi et al. 2008). However, the expression of BMP6 and BMP7 was
also noted to be reduced by estrogen treatment, indicating that estrogen also alters BMP signaling
(Takahashi et al. 2008). The fibroblast growth factor 8 (FGF8) has also been connected to BMP and
estrogen cross-talk, and it has been indicated to enhance endogenous estrogenic actions and suppress
BMP receptor signaling in ER-positive breast cancer cell lines, thus easing cell proliferation (Masuda
et al. 2011). All in all, the interaction between BMPs and estrogen has been studied quite fractionally,
and in most studies, only in MCF-7 breast cancer cell line. Thus, more information on the
BMP/estrogen –cross-talk is needed to better understand its background.
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3. Objectives
Estrogen has a significant role in breast carcinogenesis and progression, and is known to promote
breast cancer cell growth. BMPs also take part in breast cancer pathogenesis, and affect e.g. breast
cancer cell proliferation and migration. In contrast to estrogen, BMP4 has a breast cancer cell growth
reducing effect. Estrogen and BMP signaling have been noted to be interconnected, but information
on the cross-talk between them is still insufficient.
The specific aims of this study were:
1) to assess the effect of estradiol (E2) treatment to the expression levels of BMP4 and BMP7 in
breast cancer cell lines
2) to examine how the combination of E2 and BMP4 treatments affects the proliferation of breast
cancer cells.
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4. Materials and Methods
4.1. Gene expression analysis
4.1.1. Cell lines
The estrogen receptor (ER) positive human breast cancer cell lines BT-474, MCF-7, MDA-MB-361,
T-47D and ZR-75-30, and the estrogen receptor negative cell line MDA-MB-231 were obtained from
the American Type Tissue Culture Collection (ATCC, Manassas, VA, USA). The cell lines were
cultured  in  their  respective  conditions  as  presented  in  Table  1,  at  37°C  and  5%  CO2. Dulbecco’s
modified Eagle’s medium (DMEM), Eagle’s minimum essential medium (EMEM), L-15 medium,
RPMI medium, fetal bovine serum (FBS), and supplements L-glutamine, penicillin-streptomycin
solution (P/S), sodium pyruvate, sodium bicarbonate, non-essential amino acid solution (NEAA) and
HEPES buffer were obtained from Sigma-Aldrich (St. Louis, MO, USA). Protaphane human insulin
was obtained from Novo Nordisk (Bagsværd, Denmark).
Table 1: Cell line media and supplements. The glucose column indicates the glucose concentration
already existing in the medium.
Cell line Medium FBS Supplements Glucose (g/L)
BT-474 DMEM 10%  Sodium pyruvate, glucose, L-glutamine, P/S 1
MCF-7 EMEM 10% Sodium pyruvate, NEAA, sodium bicarbonate,insulin, L-glutamine, P/S 1
MDA-
MB-361 L-15 10% L-glutamine, P/S 0.9 galactose
ZR-75-30 RPMI 10% L-glutamine, P/S 2
T-47D RPMI 10% Sodium pyruvate, HEPES buffer, sodiumbicarbonate, glucose, insulin, L-glutamine, P/S 2
MDA-
MB-231 L-15 10% L-glutamine, P/S 0.9 galactose
The supplements shown in Table 1 were added as instructed by ATCC.
4.1.2. Stripping
For the estrogen treatment, the cells were seeded to 24-well plates. The number of cells used for each
cell line varied depending on their growth characteristics and is shown in Table 2. Cell numbers were
counted with Z1 Coulter Particle Counter (Beckman Coulter, Fullerton, CA, USA). The cells were
trypsinized, and 100 µl of cell solution added to 7.9 ml of the cell counter’s electrolyte solution,
Coulter ISOTON II diluent from Beckman Coulter. The cells were diluted to their respective
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numbers, shown in Table 2, in their growth medium and allowed to attach overnight on the 24-well
plate. An exception were MDA-MB-361 and MDA-MB-231 cell lines, which were normally cultured
in CO2-depleted conditions in L-15 medium, but in DMEM based medium on 24-well plates. The
medium contained the same supplements as the usual growth medium.
Table 2: Cell numbers for different cell lines for seeding to 24-well plates.
Cell line Cell number / 0.5 ml
BT-474 70 000
MCF-7 50 000
MDA-MB-361 200 000
T-47D 50 000
ZR-75-30 60 000
MDA-MB-231 10 000
The day after seeding to 24-well plates, the cells were washed twice with PBS (Sigma-Aldrich, St.
Louis, MO, USA), and the growth medium was changed to estrogen-free “stripping” medium, which
consisted of phenol-red free DMEM, 10% charcoal-stripped FBS (both by Gibco by Life
Technologies, Fischer Scientific, Waltham, MA, USA), and each cell lines’ respective supplements
as shown in Table 1. The phenol-red free DMEM did not contain glucose, so the same amount of
glucose was added to each cell lines’ estrogen depletion medium as there had been in their normal
growth mediums.
4.1.3. Estrogen treatment
The cells were cultured in the estrogen-free medium for three days, after which estrogen treatment or
vehicle treatment medium was applied. The estrogen treatment medium was prepared the same way
as the estrogen-free medium earlier, but 17β-estradiol (later called E2) (Sigma-Aldrich, St. Louis,
MO, USA) was added to a final concentration of 100 nM. The E2 was dissolved to absolute ethanol,
with stock concentration of 70.6 mM, and serially diluted into phenol-red free DMEM to achieve the
desired concentration. The vehicle medium was prepared the same way, without E2. The treatment
and vehicle media were added to the 24-well plate.
After 24h and 48h in the E2 or vehicle medium, the cells were lysed with the lysis buffer of the RNA
Plus RNA extraction kit (Macherey-Nagel, Düren, Germany) and three parallel wells were pooled.
The lysed cells were stored in -80°C freezer.
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4.1.4. RNA extraction and cDNA synthesis
RNA was extracted from the lysed cell samples with the RNA Plus RNA isolation kit by Macherey-
Nagel according to the instructions. First, genomic DNA was removed by centrifuging the sample
through a binding column. Then, RNA binding conditions were adjusted with a binding solution, and
the RNA was bound to a RNA binding column. The column was washed with washing solutions, and
the bound RNA was eluted into RNAse-free water. The RNA samples were stored in -80°C freezer.
The RNA concentrations were measured by spectrophotometry with Tecan Infinite® F200 PRO plate
reader using a NanoQuant Plate (Tecan, Männedorf, Switzerland) to ensure successful RNA
extraction.
For  qRT-PCR  analysis,  the  RNA  samples  were  synthesized  into  cDNA  with  the  Invitrogen
SuperScript® III  First-Strand  Synthesis  System for  RT-PCR (Thermo Fisher  Scientific,  Waltham,
MA, USA), using random hexamers as primers. For each sample, half of the instructed reaction
component amounts were used. To start the cDNA synthesis, 50 ng/µl random hexamer primers (0.5
µl), 10 mM dNTP mix (0.5 µl) and the RNA sample (4 µl) were incubated at 65°C for 5 minutes, and
placed on ice for at least 1 minute. The cDNA synthesis mix was prepared as shown in Table 3, and
5 µl was added to the samples, mixed, centrifuged briefly, and first incubated for 10 minutes at 25°C,
and then 50 minutes at 50°C. The reaction was terminated by incubating the samples at 85°C for 5
minutes, and the samples were chilled on ice. 0.5 µl of RNAse H (2 U/µl) was added to samples, and
the samples were incubated at 37°C for 20 minutes. The cDNA samples were stored in -20°C freezer.
Table 3: cDNA synthesis mix components in pipetting order
Component ½ reaction
10X RT buffer 1 µl
25 mM MgCl2 2 µl
0.1 M DTT 1 µl
RNAseOUT™ (40 U/µl) 0.5 µl
SuperScript® III RT (200 U/µl) 0.5 µl
4.1.5. Quantitative real-time polymerase chain reaction (qRT-PCR)
The qRT-PCR analysis was conducted using the Roche LightCycler® 2.0 device, with software
version 4.05 (Roche, Basel, Switzerland). SYBR Green I dye based assay was used for GREB1, TFF1,
BMP4 and BMP7. The GREB1 primer sequence was obtained from Rae et al. (2005), and TFF1
sequence from Bosma et al. (2002). BMP4 and BMP7 had been used earlier in the group’s research.
Primers were ordered from Sigma-Aldrich. For the housekeeping gene HPRT, TaqMan®-based
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Universal ProbeLibrary Human HPRT Gene Assay (by Roche) was used. In the SYBR Green I based
assay, LightCycler® FastStart DNA Master SYBR Green I kit by Roche was used. The gene specific
primers are shown in Table 4. The cDNA samples to be used in qRT-PCR were diluted 1:10.
Table 4: Sequences of the primers used in qRT-PCR analysis
At  the  beginning  of  the  SYBR Green  I  assay,  the  components  (shown in  Table  5)  were  mixed  to
prepare a reaction mix. 18 µl of the reaction mix was pipetted to each LightCycler® capillary, and
after that, 2 µl of the sample cDNA (1:10 dilution) was added.
Table 5: The components and their amounts in SYBR Green I qRT-PCR analysis
Components 1 x
H2O 11.6 µl
10 µM F+R primer mix (5 µM each) 2 µl
10 x LightCycler® FastStart DNA Master SYBR Green I 2 µl
25 mM MgCl2 2.4 µl
The SYBR Green I assay started with a 10 minute denaturation step at 95°C. The amplification
protocol  is  shown  in  Table  6.  After  amplification,  the  melting  curve  analysis  for  PCR  product
identification was carried out. Finally, the reaction was cooled to 40°C for 30 seconds.
Table 6: The protocol for the amplification step of qRT-PCR, differing values bolded.
Amplification, 45 cycles
Pre-incubation Denaturation Annealing Extension
Gene Time Temperature Time Temperature Time Temperature Time Temperature
GREB1 10 min 95°C 10 s 95°C 5 s 60°C 10 s 72°C
TFF1 10 min 95°C 10 s 95°C 5 s 60°C 10 s 72°C
BMP4 10 min 95°C 10 s 95°C 5 s 55°C 10 s 72°C
BMP7 10 min 95°C 10 s 95°C 5 s 55°C 13 s 72°C
For HPRT, LightCycler® TaqMan® Master reaction mix by Roche was used with a 10 minute
denaturation step at 95°C, 45 amplification cycles of 10 seconds of denaturation at 95°C, 30 seconds
of annealing at 60°C, and 1 second of elongation at 72°C, and finally 30 seconds of cooling at 40°C.
The components of one reaction included 13.2 µl of H2O, 0.4 µl of 20 µM F+R primer mix, 0.4 µl of
10 µM UPL probe, 4 µl of the TaqMan® master mix, and 2 µl of the sample cDNA (1:10 dilution).
Gene Forward primer (5’→3’) Reverse primer (5’→3’)
GREB1 CAAAGAATAACCTGTTGGCCCTGC GACATGCCTGCGCTCTCATACTTA
TFF1 GAGGCCCAGACAGAGACGTG CCCTGCAGAAGTGTCTAAAATTCA
BMP4 GGGACTTCGAGGCGACA TTCTCCAGATGTTCTTCGTGGT
BMP7 GCTTCGACAATGAGACGTTC TGGACCTCCGTGGCCTT
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4.1.6. Analysis of gene expression data
Ct (threshold cycle) values for each gene in all samples and corresponding controls were acquired in
the qRT-PCR analysis. The values were obtained with the LightCycler® software’s Fit Points –
method,  in  which  the  sample’s  exponential  curve  (as  in  Figure  5)  is  converted  to  linear.  This
exponential curve is attained by measuring the accumulating fluorescence during every cycle, which
in turn is comparable to the amount of double-stranded DNA generated in the reaction. The beginning
of the straight line is extended to cross with a horizontal crossing line, creating a crossing point (i.e.,
the threshold cycle, Ct).  The  background noise  from the  samples  was  eliminated  by  adjusting  the
noise band.
The fold change (FC) values were acquired by calculating the ΔCt’s and ΔΔCt from the following
equations (in which Ct is  the  crossing  point,  GOI  is  the  gene  of  interest,  and  normalizer  is  the
housekeeping gene HPRT).
ܥ௧	ீைூ
			ாଶ	௦௔௠௣௟௘ − ܥ௧	௡௢௥௠௔௟௜௭௘௥
			ாଶ	௦௔௠௣௟௘ 	= 	 ߂ܥ௧	ாଶ	௦௔௠௣௟௘
ܥ௧	ீைூ
			௩௘௛௜௖௟௘ −	ܥ௧	௡௢௥௠௔௟௜௭௘௥
			௩௘௛௜௖௟௘ 	= 	 ߂ܥ௧	௩௘௛௜௖௟௘
߂ܥ௧	ாଶ	௦௔௠௣௟௘ 		− 	߂ܥ	௧	௩௘௛௜௖௟௘ 	= 	 ߂߂ܥ௧Fold	change	 = 	2ି୼୼େ೟ 		
Figure 5: Screen capture from LightCycler® software depicting the amplification curves of E2 and
vehicle treated MCF-7, BT-474, ZR-75-30 and T-47D cell lines at 24h and 48h, and their Ct values.
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4.2. Functional experiments with estrogen and BMP4
4.2.1. Cell culture
BT-474 and T-47D cell lines were chosen for the functional experiments. The cells were cultured in
their usual culturing media as indicated in Table 1.
4.2.2. Estrogen and BMP4 treatment
For the estrogen and BMP4 treatment, E2 and recombinant human BMP4 protein (acquired from
R&D Systems,  Minneapolis,  MN,  USA) were  used.  E2  was  used  at  100  nM,  as  described  earlier.
Recombinant human BMP4 was used at a final concentration of 100 ng/ml, as determined earlier by
our research group (Ketolainen et al. 2010). BMP4 was diluted in vehicle solution, which consisted
of 4 mM HCl with 0.1% of bovine serum albumin (BSA). The vehicle for this experiment contained
both the estrogen vehicle made earlier for the gene expression analysis experiment, and the BMP4
vehicle.
4.2.3. Cell proliferation assay
The cells were seeded to 24-well plates for the cell proliferation assay. In the first experiments with
BT-474 and T-47D, the cells were seeded at 14000 cells per well with three parallel wells in each
treatment. For BT-474, a following experiment was conducted with cell count of 40000 cells per well,
with six parallel wells, so that statistical tests could be conducted. In following experiments with T-
47D, 40000 cells per well were seeded on the 24-well plate with six parallel wells, and repeated twice.
As earlier in the gene expression analysis experiments, the cells first needed to be depleted of
estrogen. The estrogen-“stripping” was done the same way as earlier. The cells seeded to the 24-well
plates the day before were washed with PBS, changed to estrogen-free medium, and cultured in this
medium for three days. After this, the cells were trypsinized and counted with the Z1 Coulter Particle
Counter as described earlier. The count was performed to ensure that all the wells contained same
amount of cells.
The cells on the 24-well plate were changed into treatment media containing either 100 nM 17β-
estradiol, 100 ng/ml BMP4, both, or vehicle. Fresh treatment media were changed every other day.
The  cells  were  counted  using  the  Z1  Coulter  Particle  Counter  on  day  six  or  seven  after  the  first
addition of the treatment media.
26
4.2.4. Statistical analyses for functional experiments
For experiments with six parallel samples, Mann-Whitney test was used to evaluate the statistical
difference between the differently treated samples. Grubb’s test was conducted to determine if one of
the samples was a significant outlier.
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5. Results
5.1. Effects of E2 treatment on BMP expression
The effect of E2 on breast cancer cell line’s BMP expression was studied with gene expression
analysis. The expression of the positive control genes GREB1 and TFF1, and target genes BMP4 and
BMP7 was assessed with qRT-PCR from six breast cancer cell lines: estrogen receptor (ER) positive
BT-474, MCF-7, MDA-MB-361, T-47D and ZR-75-30, and ER negative MDA-MB-231. The
positive control genes were genes known to be upregulated after estrogen treatment (Rae et al. 2005;
Sun et al. 2005). In the ER negative MDA-MB-231 cell line the positive control genes were expressed
on a very low level, and as expected, their expression did not change after E2 treatment. Similarly,
TFF1 expression levels were so low in the T-47D cell line that they could not be reliably measured.
GREB1 expression was upregulated in all ER positive cell lines (Figure 6). TFF1 expression  was
increased in BT-474, MCF-7 and MDA-MB-361, but no significant change was seen in ZR-75-30
(Figure 6).
As for target genes BMP4 and BMP7, the MDA-MB-231 cell line showed no measurable expression
for BMP7, and insignificant fold changes for BMP4 after estrogen treatment (data not shown). After
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Figure 6: Fold change values of positive control genes GREB1 and TFF1 on a logarithmic
scale. The orange line indicates a cut-off  point  for  a  fold  change  value  considered  as
significant.
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estrogen treatment, BMP4 expression was downregulated significantly in BT-474, MCF-7 (at 48
hours), and MDA-MB-361 (at 24 hours) cell lines (Figure 7). Other cell lines showed no significant
change in BMP4 expression after E2 treatment (Figure 7).
On the other hand, BT-474, T-47D, and ZR-75-30 showed downregulation of BMP7 (Figure 7). In
the case of ZR-75-30, this effect was only observed at 48 hours. MCF-7 showed small, but
insignificant decrease in BMP7 expression, whereas MDA-MB-361 had similar, insignificant change
in expression than with BMP4 (decrease at 24 hours, then increase at 48 hours). Biological replicates
for the E2 treatment were assessed with similar results, and technical replicates for qRT-PCR were
also performed.
5.2. Effects of E2 and BMP4 treatment on cell proliferation
In the functional experiments, the effect of estrogen and BMP4 treatment on breast cancer cell
proliferation was assessed by observing cell growth. Light microscope pictures of the treated cells
were taken to determine possible morphological changes caused by different treatments, and cells
were counted to quantify the differences in cell number.
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Figure 7:  Fold  changes  for  BMP4  and  BMP7 on a logarithmic scale. The orange line
indicates a cut-off point for a fold change value considered as significant.
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A
B
Figure 8: Light microscope pictures (10X magnification) of vehicle, estrogen (E2), E2 and
BMP4, and BMP4 treated (A) BT-474 cells at day 7 and (B) T-47D cells at day 5.
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The BT-474 cell morphology, seen in Figure 8A, was notably different in estrogen treated cells
compared to BMP4 treated cells, as they grew in raft-like formations as usual for this cell line, with
seemingly more cells. The vehicle treated cells made raft-like formations, but with seemingly less
cells, as did the cells treated with both estrogen and BMP4. The BMP4 treated cells on the other hand,
formed  smaller,  more  round  formations  (Figure  8A).  The  cells  seemed  to  spread  out  more  in  the
presence of estrogen, and when there was only BMP4, the cells remain in their place.
The morphology of T-47D cells, seen in Figure 8B, changed drastically when estrogen was present.
Both estrogen and estrogen and BMP4 treated cells spread out and formed a confluent layer of cells
at the bottom of the well, whereas the cells in estrogen-free environment grew in patches. The
BMP4 treatment seemed to affect the cell growth quite negatively. The E2 treated cells were most
like T-47D cells usually, when grown in the normal phenol red containing culture medium with
FBS.
The effect of different treatments on cell growth was assessed by counting the cells. The cells were
counted on day 0 (after 72h of estrogen depletion) to determine the actual amount of cells in the
wells, because the estrogen depletion affected cell growth negatively. The cells were also counted
on day 3 but no differences in growth were detected at that point (data not shown).
The count of BT-474 cells on day 7, seen in Figure 9A, showed that the vehicle control and BMP4
treated cells were the least proliferative, with around 70 000 cells/ml, when originally the cells were
seeded at 80 000 cells/ml. Estrogen treatment had a significant proliferative effect on the cells. With
the combination of E2 and BMP4 treatment, the cell count was significantly higher than with the
vehicle or BMP4 treated cells, but significantly less than with only E2 treated cells. The BT-474
cell proliferation was decreased 57% when treated with both E2 and BMP4 as compared to only E2
treated cells. The differences in cell numbers are statistically significant between all except vehicle
and BMP4 treatments.
The T-47D cell count, seen in Figure 9B, showed slightly different results comparing to BT-474
(Figure 9A) with vehicle cells. The estrogen depletion didn’t seem to affect T-47D as much, so the
difference in cell counts between vehicle and BMP4 treated cells was significant. BMP4 thus
showed a growth decreasing effect in T-47D cells. The estrogen treatment significantly increased
proliferation, whereas combined E2 and BMP4 treatment decreased it by 65% compared to the E2
treatment. There was no significant change between E2 and BMP4 combination treatment, and
BMP4 only treated cell counts, but between other treatments significant differences could be
detected.
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6. Discussion
This study aimed to evaluate the possible cross talk between estrogen and BMP signaling. First, the
possible effect of estrogen treatment on BMP4 and BMP7 expression  was  studied,  and  known
estrogen responsive genes, GREB1 and TFF1, were used as positive controls. More specifically, the
expression levels of BMP4, BMP7, GREB1 and TFF1 were screened in five ER-positive breast cancer
cell lines and one ER-negative control breast cancer cell line 24 and 48 h after estrogen treatment.
Additionally, the effect of estrogen and BMP4 treatment on the growth of two breast cancer cell lines
was studied.
The cells used in the experiments were grown in estrogen-free conditions (“stripped”) before estrogen
treatment, which notably affected cell growth. The phenol red and normal FBS -containing medium
provides the ER-positive cell lines a growth-inducing environment. Phenol red has weak estrogenic
properties, binding to ERs with a 0.001% affinity compared to estradiol (Berthois et al. 1986). It also
stimulates cell-proliferation like estrogen, in dose-dependent manner, and it is usually present in high
concentrations in cell culture media (Berthois et al. 1986). Charcoal-stripping of FBS is unspecific
and removes not only steroid hormones, but also other vital components of the serum such as folic
acid, vitamins (e.g. B12), glucose and phosphorus are extracted (Cao et  al. 2009). Untreated FBS
contains high levels of estradiol conjugates, and the charcoal stripping procedure does not necessarily
remove all of the existing conjugates, which some cells can use to convert to estradiol (Cao  et  al.
2009).  Specific  removal  of  estradiol  from  FBS  would  be  the  optimal  situation,  but  as  it  happens,
apparently no such method exists at the moment. Serum-free cell culture is an option, but also then
the cell growth would be stunted due to the absence of essential growth factors and nutrients.
6.1. Estrogen inhibits the expression of BMP4 and BMP7 in a cell line
dependent manner
In the gene expression experiments, positive control genes GREB1 and TFF1 were used to assess the
functionality of the E2 treatment. GREB1 and TFF1 expression are known to be elevated in breast
cancer cells after E2 treatment (Bosma et al. 2002; Ghosh et al. 2000; Mohammed et al. 2013; Rae
et al. 2005; Sun et al. 2005).  The  results  of  the  positive  control  gene  expression  studies  mostly
confirmed this. GREB1 expression was elevated after E2 treatment in all ER-positive cell lines, and
TFF1 expression was notably upregulated in all but ZR-75-30 cell line, and the TFF1 expression was
so low in the T-47D cell line that it could not be reliably measured. However, Rae et  al. (2005)
showed TFF1 gene expression upregulation by E2 treatment in the T-47D cell line in their study.
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Their primers for TFF1 were obtained from the study by Bosma et al. (2002) as in this study, and
other conditions were quite similar. Also, as expected, the ER-negative MDA-MB-231 cell line
demonstrated very low expression of both GREB1 and TFF1, and did not show any change after E2
treatment.
BMP4 expression after E2 treatment has not been studied before, at least not in the studies found. The
BMP4 expression was notably downregulated after E2 treatment in three of the five ER-positive cell
lines: BT-474 MCF-7 and MDA-MB-361. BT-474 was the sole cell line in which gene expression
was downregulated in both time points, and only decreased more with time. In MCF-7, BMP4 showed
insignificant decrease at 24h and barely significant decrease at 48h. In MDA-MB-361, the BMP4
expression was at first downregulated notably, but then reverted back at 48h.
The expression of BMP7 has been found to be downregulated after E2 treatment in the MCF-7 cell
line (Takahashi et al. 2008), but no other cell lines have been evaluated. In this study, the decrease in
BMP7 expression in MCF-7 cells was apparent, but did not reach the set cut-point level. However,
BMP7 expression was significantly reduced in BT-474, T-47D and ZR-75-30 cell lines. In both BT-
474 and T-47D the expression was downregulated at both time points, and in ZR-75-30 only at 48h
time point.
Taken together, it seems that E2 has different effects on the BMP expression of different cell lines.
The only cell line in which the expression of both BMP4 and BMP7 was reduced notably, was BT-
474. Different cell lines are derived from different individuals, which is why their genetic
backgrounds can be very variable (Heiser et al. 2009). Several different factors are needed to regulate
transcription, and the expression of these factors varies depending on the cell line. Moreover, other
factors than just E2 are needed to regulate BMP expression, and perhaps some of these factors were
not present in those cell lines in which E2 didn’t have a notable effect. More studies should be done
on the molecular mechanisms of E2 regulation of BMP expression to find out why it acts in such a
variable manner in breast cancer cells.
6.2. BMP4 treatment attenuates the effects of estrogen on breast cancer
cell growth
The cell proliferation experiment was conducted with two cell lines, with three days of estrogen
“stripping”, and counting the cells after six or seven days after treatment with E2, BMP4, or both.
BT-474 and T-47D cell lines were chosen for the cell proliferation experiment for two reasons: i) BT-
474 showed significant response to E2 treatment with BMP4 gene expression decreasing significantly
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and ii) BMP4 treatment had earlier been shown to decrease cell growth significantly in T-47D, BT-
474 was not used in the study (Ampuja et al. 2013; Ketolainen et al. 2010).
The effect of estrogen on BMP signaling and action has been studied more in the cell proliferation
perspective. Takahashi et al. (2008) demonstrated that BMP6 and BMP7 has a growth-inhibiting
effect on the MCF-7 cell proliferation induced by estrogen. BMP4 has not been studied in this respect,
but it has been shown to inhibit breast cancer cell growth in several breast cancer cell lines (Ampuja
et al. 2013; Ketolainen et al. 2010).
As expected, E2 significantly, and distinctly increased cell proliferation in both BT-474 and T-47D
cell lines. When treated with both estrogen and BMP4, both cell lines showed significant reduction
in cell proliferation, as in previous study using BMP6 and BMP7 (Takahashi et al. 2008). There was
no significant difference in proliferation between vehicle and BMP4 in BT-474 cells, but in T-47D
cells BMP4 treatment significantly decreased cell proliferation. This could be due to the cell line’s
different reactions to the “stripping” medium. T-47D might better tolerate the harsher environment,
and thus, the addition of BMP4 reduces growth. In T-47D the treatment with both E2 and BMP4
reduces growth to the same level as treatment with only BMP4. In BR-474, however, the E2 and
BMP4 treated cells proliferate more than only BMP4 treated cells, possibly due to the cell line’s poor
tolerance of the “stripping” medium. The effects of E2 and BMP4 could not be seen so clearly yet on
day three after treatment, which indicates that the growth reducing effects are likely to happen via
gene expression changes, and not the rapid response pathways.
Interestingly, the microscope images taken of T-47D cells on day 5 show that cells treated with both
E2 and BMP4 have spread out, and seem like there are more cells than in the BMP4 treated well,
when in fact, there are actually almost the same number of cells. This might be due to the migration
and invasion inducing effect of BMP4, and it seems that the presence of estrogen is required for the
spreading to happen. The effect is not seen with BT-474 cells. However, Ketolainen et  al. (2010)
show that migration actually decreases in T-47D cell line after BMP4 treatment. The study was not
conducted in estrogen-free environment, so it might be that the estrogen “stripping” also affects this
phenomenon.
Estrogen addition affected the morphology of both BT-474 and T-47D cells, and the cells looked
more like usual (when grown in normal conditions).  Otherwise,  the cells grew quite poorly in the
vehicle treated wells, and BMP4 treatment seemed to only intensify the suffering.
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All in all, combined E2 and BMP4 treatment of BT-474 and T-47D cells shows reduced growth
compared to only E2 treated cells. Thus, these data indicate that BMP4 is able to reverse, at least
partly, the proliferation inducing effects of estrogen. This is an important finding that may have
clinical applicability for the treatment of breast cancer patients with ER positive tumors.
6.3. Future aspects
In this study, estrogen and BMPs demonstrate their cross-talk. It seems that in some breast cancer
types, the interaction between them is more pronounced, as can be seen in the gene expression results.
More research should still be done in regard of the proliferation reducing effect of BMPs on E2
induced cell growth, and assess the effects in other cell lines. The effects of BMPs and E2 on ER-
negative cell lines should also be further studied to ensure that the effect is ER-dependent. Detailed
studies highlighting the functional cross-talk of the estrogen and BMP signaling pathways should be
done to better understand the factors that have an effect in it. Also the reasons behind why estrogen
decreases BMP expression in some cell lines and not in others could bring light to the factors playing
a role in the interactions between estrogen and BMPs.
The interaction between estrogen and BMPs has only been studied in very few breast cancer cell
lines, although a lot of them are used in research nowadays. MCF-7 cell line is the most used one, but
other cell lines should also be considered when studying E2 and BMP cross-talk, since breast cancer
is inherently a very variable disease.  Thus, breast cancer studies should be done with more cell lines
than  only  one  or  two,  and  preferably  with  cell  lines  showing  different  ER/PR  status,  ethnic
background, and other characteristics. This might help in the development of personalized medicines
and treatments for breast cancer patients with different tumor types, responding to different treatments
Furthermore, the molecular background of the interactions between E2 and BMPs in specific cell
lines should be studied in more detail to assess the central factors influencing the different effects in
different cell lines.
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7. Conclusion
The objective of this study was to assess the relationship between estrogen and bone morphogenetic
proteins in several different breast cancer cell lines. Both the effect of estrogen treatment on BMP4
and BMP7 expression, and the effect of estrogen and BMP4 on breast cancer cell proliferation were
studied in this respect. The results show that the effects of estrogen on BMP4 and BMP7 expressions
vary in different cell lines and different time points, with their expression being down-regulated in
some cell lines or not notably altered in others. The proliferation study with E2 and BMP4 treatment
showed consistent results that E2 and BMP4 treatment together reduce the proliferation induced by
E2. The findings can be used to further study the E2 and BMP interactions, and may possibly later in
the future have a clinical significance in the treatment of breast cancer patients with ER positive
tumors.
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